company background image
NMTR

9 Meters Biopharma NasdaqCM:NMTR Stock Report

Last Price

US$1.72

Market Cap

US$22.3m

7D

0.2%

1Y

-90.7%

Updated

04 Dec, 2022

Data

Company Financials +
NMTR fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

NMTR Stock Overview

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders.

9 Meters Biopharma, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for 9 Meters Biopharma
Historical stock prices
Current Share PriceUS$1.72
52 Week HighUS$21.00
52 Week LowUS$1.65
Beta0.33
1 Month Change-21.51%
3 Month Change-67.55%
1 Year Change-90.74%
3 Year Change-88.27%
5 Year Changen/a
Change since IPO-98.52%

Recent News & Updates

9 Meters Biopharma to execute 1-for-20 reverse stock split

Oct 17

Recent updates

Shareholder Returns

NMTRUS PharmaceuticalsUS Market
7D0.2%2.4%1.5%
1Y-90.7%15.5%-14.9%

Return vs Industry: NMTR underperformed the US Pharmaceuticals industry which returned 15.5% over the past year.

Return vs Market: NMTR underperformed the US Market which returned -14.9% over the past year.

Price Volatility

Is NMTR's price volatile compared to industry and market?
NMTR volatility
NMTR Average Weekly Movement14.9%
Pharmaceuticals Industry Average Movement11.0%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: NMTR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: NMTR's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a21John Temperatohttps://www.9meters.com

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications.

9 Meters Biopharma, Inc. Fundamentals Summary

How do 9 Meters Biopharma's earnings and revenue compare to its market cap?
NMTR fundamental statistics
Market CapUS$22.27m
Earnings (TTM)-US$41.39m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NMTR income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$41.39m
Earnings-US$41.39m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.19
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio136.6%

How did NMTR perform over the long term?

See historical performance and comparison